marimastat


Also found in: Wikipedia.

marimastat

A matrix metalloproteinase and angiogenesis inhibitor which had shown early promise for managing advanced malignancy; phase-III studies failed in this expectation, however. Marimastat may have a secondary role as maintenance therapy for advanced colorectal, ovarian, pancreas, prostate and other cancers.
 
Adverse effects
Musculoskeletal pain.

marimastat

Oncology An angiogenesis inhibitor and matrix metalloproteinase inhibitor in clinical trials as an ancillary therapy for advanced malignancy–ovary, pancreas, small cell of lung, stomach, glioblastoma. See Angiogenesis inhibitors.
References in periodicals archive ?
The MMP inhibitors batimastat and marimastat reduce CNV when applied early in the process [93,94], suggesting a potential therapeutic role for MMP9 inhibitors in AMD.
British Biotech was humbled in the late 1990s when its leading drug hope, a cancer treatment called Marimastat, failed clinical trials.
A recent trial evaluating the combination of marimastat (a protease inhibitor) and temozolomide reported a 6-month progression-free survival of 39% compared to 21% with temozolomide alone (Groves et al.
Once one of the bright lights of the UK sector, it was hit by the failure of cancer drug Marimastat and pancreatitis treatment Zacutex, both at one point hailed as potential blockbusters.
British Biotech, once the flagship of the UK biotechnology industry, has been looking at new products after the failure of cancer drug Marimastat.
But now it seems the treatment, Marimastat, is effective.
This trial was designed to study the effect of marimastat compared to placebo in prolonging survival of patients with glioblastoma, a form of brain cancer.
In return for exclusive rights to sell all MMPIs in any type of cancer, British Biotech will receive an up-front payment of USD8million, split between a license fee and equity investment, and could receive up to a further USD52 million in milestone payments, depending on the results of Phase III clinical trials of Marimastat currently taking place.
Overall, the company's work force has reduced by 32 per cent during the year to 311 staff and is planned to fall further to 280 as current marimastat clinical trials are completed.
BELEAGUERED biotechnology group British Biotech said yesterday their cancer drug Marimastat had failed early tests.
Currently, Marimastat, an MMPI made by British Biotech Pharmaceuticals, Ltd.
Then head of research, Dr Andrew Millar, was sacked in April after accusing directors of over-optimistic statements on experimental drugs Zacutex and Marimastat.